Data Papers Archives

RRx-001, A novel dinitroazetidine radiosensitizer.

Nov 1, 2021

Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.Invest New Drugs. 2016 Jun;34(3):371-7. doi: 10.1007/s10637-016-0326-y. Epub 2016 Feb 3.PMID: 26841903 Free PMC article. Review.

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Nov 1, 2021

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016 Jan-Apr.PMID: 26933418 Free PMC article.

$Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.$

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.

Nov 1, 2021

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.Case Rep Oncol. 2016 Jan 28;9(1):62-7. doi: 10.1159/000443725. eCollection 2016 Jan-Apr.PMID: 26933421 Free PMC article.

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis.

Nov 1, 2021

Carter CA, Browning R, Oronsky BT, Scicinski JJ, Brzezniak C.Case Rep Oncol. 2016 Jan 27;9(1):68-75. doi: 10.1159/000443723. eCollection 2016 Jan-Apr.PMID: 26933422 Free PMC article.

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Nov 1, 2021

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016 Jan-Apr.PMID: 27065848 Free PMC article.

$RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.$

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Nov 1, 2021

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C.Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.PMID: 27065849 Free PMC article.

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.

Nov 1, 2021

Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD.Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003.PMID: 27084426 Free PMC...

Rockets, radiosensitizers, and RRx-001: an origin story part I.

Nov 1, 2021

Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.Discov Med. 2016 Mar;21(115):173-80.PMID: 27115167 Review.

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.

Nov 1, 2021

Oronsky B, Scicinski J, Cabrales P, Minchinton A.Clin Epigenetics. 2016 May 11;8:53. doi: 10.1186/s13148-016-0220-7. eCollection 2016.PMID: 27175220 Free PMC article.

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

Nov 1, 2021

Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B.Med Oncol. 2016 Jul;33(7):63. doi: 10.1007/s12032-016-0775-3. Epub 2016 May 26.PMID: 27229330

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.

Nov 1, 2021

Oronsky B, Scicinski J, Reid T, Oronsky A, Carter C, Oronsky N, Cabrales P.Discov Med. 2016 Apr;21(116):251-65.PMID: 27232511

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Nov 1, 2021

Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016.PMID: 27330954 Free PMC article.

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

Nov 1, 2021

Fens MH, Cabrales P, Scicinski J, Larkin SK, Suh JH, Kuypers FA, Oronsky N, Lybeck M, Oronsky A, Oronsky B.Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. Epub 2016 Jul 4.PMID: 27377482

$Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.$

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Nov 1, 2021

Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C.Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.PMID: 27403127 Free PMC article.

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.

Nov 1, 2021

Oronsky B, Carter C, Scicinska A, Oronsky A, Oronsky N, Lybeck M, Scicinski J. Oncotarget. 2016 Feb 23;7(8):9041-5. doi: 10.18632/oncotarget.6984. PMID: 26814434; PMCID: PMC4891024.

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

Nov 1, 2021

Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B.Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205.PMID: 27007055 Free PMC article. Review.

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.

Nov 1, 2021

Das DS, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC.Leukemia. 2016 Nov;30(11):2187-2197. doi: 10.1038/leu.2016.96. Epub 2016 Apr 27.PMID: 27118403 Free PMC article.

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Nov 1, 2021

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA.Clin Med Insights Oncol. 2016 Nov 6;10:105-108. doi: 10.4137/CMO.S40429. eCollection 2016.PMID: 27840583 Free...

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Nov 1, 2021

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA.Oncol Res Treat. 2016;39(11):720-723. doi: 10.1159/000449432. Epub 2016 Sep 19.PMID: 27855386

$A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.$

A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.

Nov 1, 2021

Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25. PMID: 28444622.

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.

Nov 1, 2021

Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA.Expert Opin Investig Drugs. 2017 Jan;26(1):109-119....

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.

Nov 1, 2021

Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM.Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.PMID: 28149332 Free PMC article.

RRx-001 protects against cisplatin-induced toxicities.

Nov 1, 2021

Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P.J Cancer Res Clin Oncol. 2017 Sep;143(9):1671-1677. doi: 10.1007/s00432-017-2416-4. Epub 2017 Apr 17.PMID: 28417195

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.

Nov 1, 2021

Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B.Expert Rev Hematol. 2017 Jun;10(6):575-582. doi: 10.1080/17474086.2017.1324779. Epub 2017 May 22.PMID: 28448172 Free PMC article.

Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.

Nov 1, 2021

Huang Z, Fu J, Zhang Y.J Med Chem. 2017 Sep 28;60(18):7617-7635. doi: 10.1021/acs.jmedchem.6b01672. Epub 2017 May 23.PMID: 28505442 Review.

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

Nov 1, 2021

Brzezniak C, Oronsky B, Trepel J, Summers TA Jr, Cabrales P, Lee MJ, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck HE, Brown JF, Reid TR, Carter CA.Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017...

A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.

Nov 1, 2021

Brzezniak C, Oronsky B, Aggarwal R.Eur Urol. 2018 Feb;73(2):306-307. doi: 10.1016/j.eururo.2017.09.010. Epub 2017 Sep 21.PMID: 28943185 No abstract available.

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.

Nov 1, 2021

Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL.Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24.PMID: 29254266 Free PMC article.

A note on improved statistical approaches to account for pseudoprogression.

Nov 1, 2021

Abrouk N, Oronsky B, Caroen S, Ning S, Knox S, Peehl D.Cancer Chemother Pharmacol. 2018 Mar;81(3):621-626. doi: 10.1007/s00280-018-3529-4. Epub 2018 Feb 5.PMID: 29404682

$A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.$

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.

Nov 1, 2021

Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E.J Investig Med High Impact Case Rep. 2018 Mar 7;6:2324709618760080. doi: 10.1177/2324709618760080. eCollection 2018 Jan-Dec.PMID: 29552569 Free PMC article.

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

Nov 1, 2021

Oronsky B, Goyal S, Kim MM, Cabrales P, Lybeck M, Caroen S, Oronsky N, Burbano E, Carter C, Oronsky A.Transl Oncol. 2018 Jun;11(3):771-778. doi: 10.1016/j.tranon.2018.03.014. Epub 2018 Apr 23.PMID: 29698934 Free PMC article. Review.

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

Nov 1, 2021

Oronsky B, Reid TR, Oronsky A, Caroen S, Carter CA, Cabrales P.Oncotarget. 2018 May 4;9(34):23439-23442. doi: 10.18632/oncotarget.25211. eCollection 2018 May 4.PMID: 29805745 Free PMC article.

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.

Nov 1, 2021

Oronsky B, Oronsky N, Cabrales P.J Cell Mol Med. 2018 Oct;22(10):5076-5082. doi: 10.1111/jcmm.13791. Epub 2018 Jul 16.PMID: 30010241 Free PMC article.

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.

Nov 1, 2021

Ojemuyiwa M, Zeman K, Spira A, Oronsky B, Ray C, Trepel JB, Lee MJ, Onyiuke I, Brzezniak C.Clin Case Rep. 2018 Nov 5;6(12):2478-2481. doi: 10.1002/ccr3.1880. eCollection 2018 Dec.PMID: 30564353 Free PMC article.

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-alpha on Monocytes/Macrophages.

Nov 1, 2021

Cabrales P.Transl Oncol. 2019 Apr;12(4):626-632. doi: 10.1016/j.tranon.2018.12.001. Epub 2019 Feb 6.PMID: 30738349 Free PMC article.

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.

Nov 1, 2021

Morra F, Merolla F, Criscuolo D, Insabato L, Giannella R, Ilardi G, Cerrato A, Visconti R, Staibano S, Celetti A.J Exp Clin Cancer Res. 2019 Feb 20;38(1):90. doi: 10.1186/s13046-019-1087-1.PMID: 30786932 Free PMC article.

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.

Nov 1, 2021

Criscuolo D, Morra F, Giannella R, Visconti R, Cerrato A, Celetti A.J Exp Clin Cancer Res. 2019 Feb 22;38(1):91. doi: 10.1186/s13046-019-1089-z.PMID: 30791940 Free PMC article. Review.

Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.

Nov 1, 2021

Oronsky B, Ao-Ieong ESY, Yalcin O, Carter CA, Cabrales P.Mol Pharm. 2019 Jul 1;16(7):2929-2934. doi: 10.1021/acs.molpharmaceut.9b00150. Epub 2019 Jun 3.PMID: 31038318

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.

Nov 1, 2021

Morgensztern D, Rose M, Waqar SN, Morris J, Ma PC, Reid T, Brzezniak CE, Zeman KG, Padmanabhan A, Hirth J, I Spira A, Trepel JB, Padda SK.Br J Cancer. 2019 Jul;121(3):211-217. doi: 10.1038/s41416-019-0504-8. Epub 2019 Jun 24.PMID: 31231122 Free PMC article.

RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition.

Nov 1, 2021

Oronsky B, Scribner C, Aggarwal R, Cabrales P.J Cancer Res Clin Oncol. 2019 Aug;145(8):2045-2050. doi: 10.1007/s00432-019-02958-4. Epub 2019 Jun 27.PMID: 31250159

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.

Nov 1, 2021

Oronsky B, Reid TR, Larson C, Caroen S, Quinn M, Burbano E, Varner G, Thilagar B, Brown B, Coyle A, Ferry L, Abrouk N, Oronsky A, Scribner CL, Carter CA.Future Oncol. 2019 Oct;15(30):3427-3433. doi: 10.2217/fon-2019-0317. Epub 2019 Sep 11.PMID: 31509028 Clinical...

Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001.

Nov 1, 2021

Cirrik S, Ugurel E, Aksu AC, Oronsky B, Cabrales P, Yalcin O.Biorheology. 2019;56(4):221-235. doi: 10.3233/BIR-190213.PMID: 31640080

BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases.

Nov 1, 2021

Kim MM, Parmar HA, Schipper M, Devasia T, Aryal MP, Kesari S, O'Day S, Morikawa A, Spratt DE, Junck L, Mammoser A, Hayman JA, Lawrence TS, Tsien CI, Aiken R, Goyal S, Abrouk N, Trimble M, Cao Y, Lao CD.Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):478-486. doi:...

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix.

Nov 1, 2021

Caroen S, Oronsky B, Carter C, Lybeck M, Oronsky A, Reid T.Expert Opin Drug Deliv. 2020 Jun;17(6):741-742. doi: 10.1080/17425247.2020.1761787. Epub 2020 Apr 30.PMID: 32331501

A Biomimetic Nanogenerator of Reactive Nitrogen Species Based on Battlefield Transfer Strategy for Enhanced Immunotherapy.

Nov 1, 2021

Feng Q, Li Y, Wang N, Hao Y, Chang J, Wang Z, Zhang X, Zhang Z, Wang L.Small. 2020 Jun;16(25):e2002138. doi: 10.1002/smll.202002138. Epub 2020 May 28.PMID: 32468692

Just eat it: A review of CD47 and SIRP-α antagonism.

Nov 1, 2021

Oronsky B, Carter C, Reid T, Brinkhaus F, Knox SJ.Semin Oncol. 2020 Apr-Jun;47(2-3):117-124. doi: 10.1053/j.seminoncol.2020.05.009. Epub 2020 May 30.PMID: 32517874 Review.

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.

Nov 1, 2021

Oronsky B, Knox S, Cabrales P, Oronsky A, Reid TR.Semin Oncol. 2020 Oct;47(5):305-308. doi: 10.1053/j.seminoncol.2020.07.002. Epub 2020 Jul 7.PMID: 32718560 Free PMC article.

Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.

Nov 1, 2021

Lee MJ, Tomita Y, Yuno A, Lee S, Abrouk NE, Oronsky B, Caroen S, Trepel JB.Expert Opin Investig Drugs. 2021 Feb;30(2):177-183. doi: 10.1080/13543784.2021.1863947. Epub 2021 Jan 11.PMID: 33306414 Clinical Trial.

RRx-001, a downregulator of the CD47- SIRPalpha checkpoint pathway, does not cause anemia or thrombocytopenia.

Nov 1, 2021

Oronsky B, Cabrales P, Caroen S, Guo X, Scribner C, Oronsky A, Reid TR.Expert Opin Drug Metab Toxicol. 2021 Apr;17(4):355-357. doi: 10.1080/17425255.2021.1876025. Epub 2021 Jan 22.PMID: 33432831

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an “erythrophagoimmunotherapeutic”.

Nov 1, 2021

Oronsky B, Carter CA, Caroen S, Scribner C, Oronsky A, Reid TR.Oncoimmunology. 2020 Apr 3;9(1):1746172. doi: 10.1080/2162402X.2020.1746172.PMID: 33457091 Free PMC article.